Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Incyte Corp (INCY)

Incyte Corp (INCY)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
60.91 +0.36 (+0.59%) 04/01/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 60.91 unch (unch) 16:42 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
60.28
Day High
62.00
Open 60.53
Previous Close 60.55 60.55
Volume 2,575,600 2,575,600
Avg Vol 2,109,105 2,109,105
Stochastic %K 19.81% 19.81%
Weighted Alpha +0.66 +0.66
5-Day Change -1.17 (-1.88%) -1.17 (-1.88%)
52-Week Range 50.35 - 83.95 50.35 - 83.95
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,717,879
  • Shares Outstanding, K 193,524
  • Annual Sales, $ 4,241 M
  • Annual Income, $ 32,610 K
  • EBIT $ 61 M
  • EBITDA $ 151 M
  • 60-Month Beta 0.76
  • Price/Sales 2.77
  • Price/Cash Flow 109.46
  • Price/Book 3.39

Options Overview Details

View History
  • Implied Volatility 38.70% ( +1.84%)
  • Historical Volatility 35.84%
  • IV Percentile 65%
  • IV Rank 45.16%
  • IV High 63.71% on 03/11/25
  • IV Low 18.10% on 05/16/24
  • Put/Call Vol Ratio 0.08
  • Today's Volume 1,001
  • Volume Avg (30-Day) 1,493
  • Put/Call OI Ratio 0.37
  • Today's Open Interest 22,763
  • Open Int (30-Day) 32,407

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.75
  • Number of Estimates 7
  • High Estimate 1.03
  • Low Estimate 0.52
  • Prior Year 0.38
  • Growth Rate Est. (year over year) +97.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
58.46 +4.19%
on 03/18/25
Period Open: 73.50
73.45 -17.07%
on 03/03/25
-12.59 (-17.13%)
since 02/28/25
3-Month
58.46 +4.19%
on 03/18/25
Period Open: 69.07
76.96 -20.85%
on 02/07/25
-8.16 (-11.81%)
since 12/31/24
52-Week
50.35 +20.97%
on 04/30/24
Period Open: 56.64
83.95 -27.44%
on 11/08/24
+4.27 (+7.54%)
since 04/01/24

Most Recent Stories

More News
Incyte Stock: Is INCY Outperforming the Health Care Sector?

Incyte has outperformed the health care sector over the past year, and analysts are moderately optimistic about the stock’s prospects.

XLV : 143.34 (-1.83%)
ALNY : 255.76 (-5.28%)
INCY : 60.91 (+0.59%)
3 Reasons INCY is Risky and 1 Stock to Buy Instead

3 Reasons INCY is Risky and 1 Stock to Buy Instead

META : 586.00 (+1.67%)
INCY : 60.91 (+0.59%)
Knight Therapeutics Announces Launch of Minjuvi® (tafasitamab) in Mexico

GUD.TO : 6.17 (+0.33%)
INCY : 60.91 (+0.59%)
Why Incyte Stock Was Tanking This Week

A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. The gloom this produced was pushing the biotech's share...

INCY : 60.91 (+0.59%)
1 Healthcare Stock on Our Watchlist and 2 to Brush Off

1 Healthcare Stock on Our Watchlist and 2 to Brush Off

UFPT : 203.93 (+1.10%)
LNTH : 97.93 (+0.34%)
INCY : 60.91 (+0.59%)
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

NTRA : 140.65 (-0.54%)
EXAS : 43.45 (+0.37%)
INCY : 60.91 (+0.59%)
REGN : 617.00 (-2.72%)
Stocks Settle Lower as Megacap Tech Stocks Routed

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -1.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.62%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.66%. March E-mini...

MSTR : 306.02 (+6.16%)
GOOGL : 157.07 (+1.57%)
AAPL : 223.19 (+0.48%)
ETR : 85.66 (+0.20%)
SRPT : 61.91 (-2.99%)
ADI : 199.18 (-1.23%)
ELV : 432.68 (-0.52%)
TSLA : 268.46 (+3.59%)
WTW : 337.00 (-0.28%)
SPY : 560.97 (+0.28%)
META : 586.00 (+1.67%)
MU : 88.71 (+2.09%)
INCY Stock Down on Disappointing Skin Disease Study Data

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis suppurativa...

BMRN : 67.94 (-3.89%)
INCY : 60.91 (+0.59%)
GILD : 111.28 (-0.69%)
GSK : 37.87 (-2.25%)
Stocks Retreat on Weakness in Technology Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -1.15%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.89%. March E-mini S&P futures...

MSTR : 306.02 (+6.16%)
GOOGL : 157.07 (+1.57%)
UAL : 68.20 (-1.23%)
CVS : 67.98 (+0.34%)
ETR : 85.66 (+0.20%)
AVGO : 168.52 (+0.65%)
SRPT : 61.91 (-2.99%)
$IUXX : 19,436.42 (+0.82%)
UNH : 523.12 (-0.12%)
ELV : 432.68 (-0.52%)
ZNM25 : 111-225 (-0.07%)
MSFT : 382.19 (+1.81%)
Stocks Slide on Economic Growth Concerns

The S&P 500 Index ($SPX ) (SPY ) today is down -1.01%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.50%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.73%. March E-mini S&P futures...

MSTR : 306.02 (+6.16%)
GOOGL : 157.07 (+1.57%)
MPC : 146.63 (+0.65%)
ETR : 85.66 (+0.20%)
AVGO : 168.52 (+0.65%)
SRPT : 61.91 (-2.99%)
$IUXX : 19,436.42 (+0.82%)
BWA : 28.54 (-0.38%)
ZNM25 : 111-225 (-0.07%)
MSFT : 382.19 (+1.81%)
TSLA : 268.46 (+3.59%)
ESM25 : 5,656.75 (-0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 63.57
2nd Resistance Point 62.78
1st Resistance Point 61.85
Last Price 60.91
1st Support Level 60.13
2nd Support Level 59.34
3rd Support Level 58.41

See More

52-Week High 83.95
Fibonacci 61.8% 71.11
Fibonacci 50% 67.15
Fibonacci 38.2% 63.19
Last Price 60.91
52-Week Low 50.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies